Codonopsis Pilosula Root

The dosage of Codonopsis Pilosula Root extract is not measured in milligrams, but rather in concentrations or dilutions relative to the weight of the source material (e.g., a 1:10 or 1:20 w/v ratio).

• Percutaneous Testing (Skin Prick): Usually, one drop of the 1:10 or 1:20 w/v (weight/volume) glycerinated extract is applied to the skin, followed by a prick or scratch through the drop.
• Intradermal Testing: If the prick test is negative but clinical suspicion remains high, a healthcare provider may inject 0.02 mL to 0.05 mL of a much more dilute concentration (e.g., 1:1000 or 1:500 w/v) into the dermal layer of the skin.

Codonopsis Pilosula Root extract may be used in children under the strict supervision of a pediatric allergist.

• Infants and Children: The procedure is identical to adult testing, though the number of tests performed in a single session may be limited to minimize discomfort and the risk of systemic reactions.
• Dosage Adjustment: No specific volume adjustment is required for children, but the healthcare provider will carefully select the concentration to minimize the risk of a systemic reaction in highly sensitive pediatric patients.

Renal Impairment

No dosage adjustment is typically required for patients with renal impairment, as the systemic exposure to the extract is minimal. However, patients with end-stage renal disease may have altered skin reactivity (uremic pruritus), which can make the interpretation of skin tests difficult.

Hepatic Impairment

No dosage adjustment is required for patients with hepatic impairment. The metabolism of the allergenic proteins is localized and does not rely on hepatic function.

Elderly Patients

In elderly patients, skin reactivity may be diminished due to age-related changes in skin turgor and mast cell density. Healthcare providers may need to use a positive control (histamine) to ensure the patient's skin is capable of mounting a response before interpreting a negative Codonopsis test.

Codonopsis Pilosula Root extract is administered exclusively by healthcare professionals in a clinical setting equipped to handle emergency reactions.

1. 1Preparation: The skin (usually the forearm or back) is cleaned with alcohol.
2. 2Application: For prick testing, a drop of the extract is placed on the skin. A sterile lancet is used to gently puncture the skin surface.
3. 3Observation: The patient must remain in the office for at least 15 to 30 minutes. The healthcare provider will then measure the diameter of any wheal (bump) and flare (redness) that develops.
4. 4Storage: The extract must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). It should not be frozen, as freezing can denature the allergenic proteins, rendering the test inaccurate.

Since this extract is used for diagnostic testing or scheduled immunotherapy in a clinic, a 'missed dose' simply refers to a missed appointment. If a diagnostic test is missed, it should be rescheduled. If the extract is being used for immunotherapy, the allergist will follow a specific 'build-up' or 'maintenance' schedule; missing a dose may require a temporary reduction in the next dose to ensure safety.

An 'overdose' in the context of an allergenic extract occurs when too much allergen is introduced, or the concentration is too high for the patient's sensitivity level, leading to a systemic reaction.

• Signs of Overdose/Systemic Reaction: Generalized hives, itching, swelling of the throat, wheezing, shortness of breath, or a drop in blood pressure (anaphylaxis).
• Emergency Measures: Immediate administration of epinephrine (EpiPen) is the first-line treatment. Other measures include oxygen, intravenous fluids, and antihistamines.

> Important: Follow your healthcare provider's instructions regarding the discontinuation of antihistamines before testing. Do not attempt to use these extracts outside of a medical facility.

Because the purpose of the extract is to elicit an immune response in sensitive individuals, localized reactions are expected and common.

• Local Wheal and Flare: A raised, itchy bump at the site of the test. This is the intended diagnostic result. It typically peaks at 15-20 minutes and resolves within a few hours.
• Localized Pruritus (Itching): Intense itching at the site of application. This can be managed with cool compresses after the test results have been recorded.
• Erythema (Redness): Redness surrounding the test site, which may feel warm to the touch.

• Delayed Local Reaction: Some patients may experience a 'late-phase' reaction where the swelling returns or worsens 4 to 8 hours after the test. This is usually not dangerous but can be uncomfortable.
• Persistent Itching: Itching that lasts for more than 24 hours at the site of the skin test.
• Local Bruising: Occasionally, the lancet used for the prick test may cause a small bruise (ecchymosis).

• Lymphangitis: Inflammation of the lymphatic channels leading away from the test site, appearing as red streaks.
• Large Local Reactions: Swelling that extends significantly beyond the test site (e.g., involving the entire forearm).
• Vasovagal Response: Fainting or lightheadedness due to the anxiety of the needle prick rather than the extract itself.

> Warning: Stop the procedure and call for emergency medical help immediately if you experience any of the following systemic symptoms after exposure to Codonopsis Pilosula Root extract:

• Anaphylaxis: A severe, life-threatening allergic reaction that can affect multiple organ systems.
• Respiratory Distress: Wheezing, chest tightness, or difficulty breathing, which may indicate bronchospasm.
• Angioedema: Significant swelling of the lips, tongue, or throat that can obstruct the airway.
• Hypotension: A sudden drop in blood pressure, leading to dizziness, confusion, or loss of consciousness.
• Generalized Urticaria: Hives appearing on parts of the body far away from the test site.

There are no known long-term side effects associated with the one-time diagnostic use of Codonopsis Pilosula Root extract. In the context of long-term immunotherapy (allergy shots), there is a theoretical risk of developing new sensitivities, though this is rare. Prolonged use of glycerinated extracts in immunotherapy can occasionally cause localized tissue changes at the injection site, such as subcutaneous atrophy (thinning of the fat layer).

While Codonopsis Pilosula Root specifically may not have a unique black box warning, the FDA requires a general Black Box Warning for many allergenic extracts regarding the risk of severe systemic reactions.

Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients should only be tested or treated in facilities where emergency equipment and trained personnel are immediately available. Patients should be observed for at least 30 minutes following administration. Those with unstable asthma or those taking beta-blockers may be at increased risk and may be more resistant to standard resuscitation measures.

Report any unusual symptoms or delayed reactions to your healthcare provider immediately.

Codonopsis Pilosula Root extract is intended for diagnostic and therapeutic use by specialists only. It is not a dietary supplement in this form and must not be ingested. The most critical safety consideration is the potential for an immediate Type I hypersensitivity reaction, which can escalate to anaphylaxis.

No specific FDA black box warning exists exclusively for Codonopsis Pilosula Root, but it falls under the general mandate for allergenic extracts: WARNING: RISKS OF SYSTEMIC REACTIONS. This includes the necessity for clinical observation and the availability of emergency resuscitation equipment including epinephrine, oxygen, and airway management tools.

• Allergic Reactions / Anaphylaxis Risk: The risk is highest during intradermal testing or during the 'build-up' phase of immunotherapy. Patients with a history of severe reactions to other botanical allergens should be approached with extreme caution.
• Asthma Status: Patients with uncontrolled or severe asthma are at a significantly higher risk for a fatal systemic reaction if they experience anaphylaxis during testing. Testing should be postponed until asthma is well-controlled.
• Beta-Blocker Use: Patients taking beta-blockers (medications for blood pressure or heart rate) may not respond effectively to epinephrine if an emergency occurs. This is a critical safety consideration that must be discussed with the allergist.
• Acute Illness: Testing should be avoided if the patient is suffering from an acute febrile illness or a significant flare-up of their allergic symptoms (e.g., severe hay fever or hives).

• Immediate Observation: The patient must be monitored for at least 30 minutes post-administration for signs of systemic distress.
• Baseline Lung Function: In patients with asthma, a baseline peak flow or spirometry measurement may be taken before testing.
• Skin Condition: The healthcare provider must monitor the skin for excessive reactions or signs of infection at the test site.

Generally, diagnostic testing does not interfere with the ability to drive. However, if a patient experiences a vasovagal response (fainting) or a mild systemic reaction requiring antihistamines (which can cause drowsiness), they should not drive until they are fully recovered and the effects of any rescue medications have worn off.

Alcohol should be avoided on the day of allergy testing. Alcohol can increase blood flow to the skin (vasodilation), which may lead to 'false positive' results or exacerbate the size of an allergic wheal.

For diagnostic testing, the procedure is a one-time event. For immunotherapy, discontinuation should be managed by the allergist. Stopping immunotherapy abruptly is generally safe but will result in the loss of clinical desensitization over time.

> Important: Discuss all your medical conditions, especially respiratory or cardiac issues, with your healthcare provider before starting Codonopsis Pilosula Root testing.

• Beta-Blockers (e.g., Propranolol, Atenolol): While not an absolute contraindication for a simple prick test, they are often contraindicated during intradermal testing and immunotherapy. The interaction is pharmacodynamic: beta-blockers antagonize the effects of epinephrine, making it difficult to treat anaphylaxis if it occurs.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine, leading to a dangerous spike in blood pressure if emergency treatment is required.

• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the pressor (blood pressure-raising) effects of epinephrine.
• ACE Inhibitors (e.g., Lisinopril): Some studies suggest patients on ACE inhibitors may experience more severe anaphylactic reactions, though the data is less definitive than with beta-blockers.

• Antihistamines (H1 Blockers): Drugs like Cetirizine (Zyrtec), Loratadine (Claritin), and Diphenhydramine (Benadryl) must be stopped 3 to 7 days before testing. These drugs block the H1 receptors on blood vessels, preventing the 'wheal and flare' from forming even if the patient is allergic, leading to a false-negative result.
• H2 Blockers (e.g., Famotidine): While less potent than H1 blockers, they can also slightly suppress the skin's response to allergens.
• Topical Corticosteroids: If applied directly to the test site, these can suppress the local immune response and should be discontinued at the site of testing for at least 2 weeks.

• Cross-Reactive Foods: Patients allergic to Codonopsis may show cross-reactivity with other members of the Campanulaceae family (e.g., Balloon Flower/Platycodon) or certain members of the Asteraceae family. Ingesting these foods shortly before testing might increase the risk of a systemic reaction.
• Caffeine: High doses of caffeine may slightly alter heart rate and blood pressure, complicating the monitoring of a patient during a systemic reaction.

• Codonopsis Supplements: If a patient is taking oral Dangshen (Codonopsis) supplements, they should inform their doctor. High systemic levels of the herb may increase the sensitivity of the diagnostic test or increase the risk of an adverse reaction during testing.
• St. John's Wort: May interact with medications used in emergency resuscitation.

• Skin Test Suppression: As mentioned, antihistamines and certain antidepressants will interfere with the results of the skin test.
• IgE Blood Tests: The administration of the extract for a skin test does not typically interfere with the results of an In Vitro (blood) IgE test, provided the blood is drawn before the skin test or several days after.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any 'natural' energy boosters which may contain Codonopsis.

• Previous Severe Systemic Reaction: Codonopsis Pilosula Root extract must NEVER be used in patients who have previously experienced life-threatening anaphylaxis to this specific extract.
• Unstable Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) of less than 70% of predicted, or those with recent acute exacerbations, are at too high a risk for fatal bronchospasm during testing.
• Acute Infection: Testing is contraindicated during active infections to avoid confusing symptoms of the infection with an allergic reaction.

• Pregnancy: While not strictly prohibited, elective diagnostic skin testing is usually postponed until after delivery to avoid the risk of anaphylaxis-induced fetal hypoxia (oxygen deprivation).
• Severe Dermatitis/Eczema: If the skin is extensively involved with eczema, there may not be enough 'clear' skin to perform an accurate test, and the hyper-irritable state of the skin can lead to false positives (dermatographism).
• Beta-Blocker Therapy: Requires a careful risk-benefit analysis by the allergist.

Patients with known allergies to other members of the Campanulaceae family (such as Lobelia or Campanula flowers) may exhibit cross-sensitivity to Codonopsis Pilosula Root. There is also documented cross-reactivity between Codonopsis and certain other botanical extracts used in traditional medicine; however, clinical data on specific cross-reactive proteins is still emerging.

> Important: Your healthcare provider will evaluate your complete medical history, including your current respiratory status, before prescribing or administering Codonopsis Pilosula Root extract.

Pregnancy Category: C (General for allergenic extracts). There are no adequate and well-controlled studies of Codonopsis Pilosula Root extract in pregnant women. Animal reproduction studies have not been conducted. The primary concern during pregnancy is not the extract itself, but the potential for a systemic reaction (anaphylaxis) in the mother. Anaphylaxis can cause a sudden drop in maternal blood pressure, leading to placental hypoperfusion and fetal distress or death. Therefore, diagnostic skin testing is typically deferred until the postpartum period unless the information is critical for immediate management.

It is not known whether the allergenic proteins from Codonopsis Pilosula Root extract are excreted in human milk. Because systemic absorption following a skin prick test is minimal, the risk to a nursing infant is considered extremely low. However, healthcare providers should weigh the benefits of diagnostic testing against any potential risks.

Codonopsis Pilosula Root extract is used in the pediatric population for the diagnosis of allergies. Safety and effectiveness have been established based on the long-standing clinical use of botanical extracts in children. Special care must be taken to use the smallest effective volume and to monitor children closely, as they may be less able to articulate early symptoms of a systemic reaction (e.g., 'itchy throat' or 'feeling of doom').

Clinical studies of allergenic extracts generally do not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In older adults, skin test reactivity may be diminished. Additionally, the prevalence of comorbid conditions (such as cardiovascular disease) and the use of medications like beta-blockers or ACE inhibitors in the elderly require more cautious testing protocols.

There is no evidence that renal impairment significantly alters the response to or the safety of Codonopsis Pilosula Root extract. However, the presence of uremia in advanced renal failure can cause skin changes that interfere with the interpretation of wheal and flare results.

No specific studies have been conducted in patients with hepatic impairment. Given the localized nature of the diagnostic procedure and the proteinaceous structure of the allergen, hepatic function is not expected to play a significant role in the drug's safety or efficacy.

> Important: Special populations, particularly pregnant women and those with chronic respiratory disease, require an individualized medical assessment before undergoing allergy testing.

Codonopsis Pilosula Root extract functions as an antigenic provocation agent. The extract contains a complex mixture of proteins, glycoproteins, and polysaccharides derived from the root of the plant. In a sensitized individual, these proteins act as allergens.

The primary molecular mechanism involves the binding of these allergenic proteins to specific IgE antibodies that are already bound to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils. This binding causes the receptors to cluster (cross-link), which activates intracellular signaling pathways (including tyrosine phosphorylation). This leads to the sudden release of inflammatory mediators from the cells' granules. The resulting localized inflammatory response is what allows the clinician to diagnose the allergy.

• Onset of Action: The immediate hypersensitivity reaction (wheal and flare) typically begins within 5 minutes of skin contact.
• Peak Effect: The maximum size of the skin reaction is usually reached between 15 and 20 minutes.
• Duration of Effect: The visible wheal and flare usually subside within 1 to 2 hours, although the underlying immunological priming at the site may last longer.
• Tolerance: Repeated skin testing at the same site over a short period can lead to 'tachyphylaxis' or diminished mast cell responsiveness due to mediator depletion.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Percutaneous); Low (Intradermal) |

| Protein Binding | High (binds to specific IgE) |

| Half-life | Localized proteins degraded within hours |

| Tmax | 15-20 minutes (Pharmacodynamic peak) |

| Metabolism | Local proteolytic degradation |

| Excretion | Lymphatic clearance of fragments |

• Molecular Components: Contains various pectic polysaccharides, polyacetylenes (such as lobetyolin), and saponins. The allergenic fraction consists primarily of water-soluble proteins.
• Solubility: The extract is prepared in an aqueous solution, often with 50% glycerin for stability.
• Storage: Must be maintained at a stable temperature (2-8°C) to prevent protein denaturation.

Codonopsis Pilosula Root belongs to the therapeutic class of Allergenic Extracts. Specifically, it is a non-standardized extract. It is grouped with other botanical extracts like Ginseng, Echinacea, or common food allergens used for diagnostic purposes. Within the EPC (Established Pharmacologic Class), it is categorized as a Non-Standardized Food Allergenic Extract.